

PHARMACEUTICAL 2022

## IMPEL PHARMACEUTICALS INC Rank 349 of 466









PHARMACEUTICAL 2022

## IMPEL PHARMACEUTICALS INC Rank 349 of 466



The relative strengths and weaknesses of IMPEL PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of IMPEL PHARMACEUTICALS INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 22% points. The greatest weakness of IMPEL PHARMACEUTICALS INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 64% points.

The company's Economic Capital Ratio, given in the ranking table, is 19%, being 59% points below the market average of 78%.

| Input Variable                              | Value in<br>1000 USD |
|---|----------------------|
| Assets, Current                             | 94,576               |
| Cost of Goods Sold                          | 691                  |
| Intangible Assets                           | 0                    |
| Liabilities, Current                        | 15,954               |
| Liabilities, Non-Current                    | 29,450               |
| Other Assets                                | 187                  |
| Other Compr. Net Income                     | 0                    |
| Other Expenses                              | 2.0                  |
| Other Liabilities                           | 0                    |
| Other Net Income                            | -5,048               |
| Other Revenues                              | 668                  |
| Property and Equipment                      | 3,149                |
| Research and Development                    | 20,563               |
| Selling, General and Administrative Expense | 50,900               |

| Output Variable          | Value in<br>1000 USD |
|--------------------------|----------------------|
| Assets                   | 97,912               |
| Liabilities              | 45,404               |
| Expenses                 | 72,156               |
| Revenues                 | 668                  |
| Stockholders Equity      | 52,508               |
| Net Income               | -76,536              |
| Comprehensive Net Income | -76,536              |
| Economic Capital Ratio   | 19%                  |

